Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Reaches New 52-Week Low After Earnings Miss
Shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) reached a new 52-week low during trading on Thursday after the company announced weaker than expected quarterly earnings. The stock traded as low as $1.02 and last traded at $1.02, with a volume of 739,938 shares traded. The stock had previously closed at $1.12.
The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.01. Aralez Pharmaceuticals had a negative net margin of 133.92% and a negative return on equity of 66.74%. The firm had revenue of $27.62 million for the quarter, compared to the consensus estimate of $21.37 million. During the same period in the previous year, the company posted ($0.27) earnings per share. Aralez Pharmaceuticals’s quarterly revenue was up 119.6% on a year-over-year basis.
A number of equities analysts recently commented on ARLZ shares. ValuEngine lowered Aralez Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Chardan Capital dropped their price target on Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating for the company in a research note on Thursday.
In other Aralez Pharmaceuticals news, Director Jason Aryeh sold 388,685 shares of the company’s stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $1.44, for a total transaction of $559,706.40. Following the sale, the director now directly owns 15,000 shares in the company, valued at $21,600. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Andrew I. Koven sold 161,906 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $1.28, for a total value of $207,239.68. Following the sale, the insider now owns 1,363,695 shares in the company, valued at $1,745,529.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 569,115 shares of company stock valued at $790,719. 6.70% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Broadfin Capital LLC increased its stake in shares of Aralez Pharmaceuticals by 8.3% in the first quarter. Broadfin Capital LLC now owns 5,191,590 shares of the company’s stock worth $11,110,000 after buying an additional 400,000 shares during the period. KCG Holdings Inc. bought a new stake in shares of Aralez Pharmaceuticals during the first quarter worth about $310,000. Isthmus Partners LLC increased its stake in shares of Aralez Pharmaceuticals by 4.9% in the first quarter. Isthmus Partners LLC now owns 153,102 shares of the company’s stock worth $328,000 after buying an additional 7,110 shares during the period. Salzhauer Michael increased its stake in shares of Aralez Pharmaceuticals by 4.5% in the second quarter. Salzhauer Michael now owns 106,293 shares of the company’s stock worth $144,000 after buying an additional 4,600 shares during the period. Finally, Norges Bank bought a new stake in shares of Aralez Pharmaceuticals during the fourth quarter worth about $665,000. Institutional investors and hedge funds own 35.61% of the company’s stock.
The stock’s 50 day moving average price is $1.32 and its 200 day moving average price is $2.17. The company’s market cap is $67.82 million.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.